QMUL “studying” PACE data-release ruling

Share on facebook
Share on twitter
Share on email

Queen Mary University of London (QMUL) have issued a statement in response to Tuesday’s tribunal ruling that they must release anonymised PACE trial data to a patient who requested it under the Freedom of Information Act.

The data would allow the calculation of main outcome and recovery figures using analyses that were specified in PACE’s original protocol but abandoned during the trial. The protocol-specified results are expected to reduce estimates of recovery in PACE very considerably, in what is likely to be an embarrassing outcome for the authors and the journals who published their work.

QMUL said, “This has been a complex case and the Tribunal’s decision is lengthy. We are studying the decision carefully and considering our response, taking into account the interests of trial participants and the research community.”

Over forty scientists and clinicians from the ME/CFS research community signed an open letter to The Lancet in February asking for independent reanalysis of the PACE data, but QMUL’s statement makes no reference to it.

QMUL added that they had “shared data from the PACE trial with other researchers only when there is a confidentiality agreement in place and an agreed pre-specified statistical plan for data analysis.”

Tom Kindlon, a patient whose critical analyses of PACE have been published in the medical literature, said, “QMUL’s statement that they have only shared data with researchers who have an agreed, prespecified statistical analysis plan in place is spectacularly ironic. If they had stuck to their own protocol-specified analysis plan in the first place, Alem Matthees would never have been forced to ask for the anonymised data.”

Alem Matthees, who made the data request, said, “Both the Tribunal’s decision and commentary are a long overdue victory for the patient community, as well as for advocates of clinical trial transparency and open data sharing. I want to thank everyone who gave support, advice or assistance.” He added, “This case ended up costing me greatly in time, energy, and health” and said that he was “currently bedridden”.

“Claims of clinically significant improvement may be open to interpretation, but false or misleading claims of full recovery from debilitating illness simply have no place in the scientific literature.”

— Alem Matthees

He said, “I utilised the Freedom of Information Act to loosen the vice-grip control over the data and allow truly independent and open analyses that do not rely on the approval of QMUL or the PACE trial investigators.” He described the PACE authors’ changes to the analysis protocol as “questionable and poorly or erroneously justified”. He said, “Claims of clinically significant improvement may be open to interpretation, but false or misleading claims of full recovery from debilitating illness simply have no place in the scientific literature.”

Reaction to the tribunal’s decision from academic critics of the PACE trial has been positive, although there are concerns that QMUL might attempt to appeal the decision. Such an appeal, however, can now only be made on the basis that the law has been incorrectly applied, rather than on the basis of fact or new argument.

Dr. David Tuller, whose 14,000-word critique of the PACE trial in October drew wide scientific attention to the problems with the trial, described the ruling as “fantastic news” and “a huge win for science and for patients”. He tweeted: “PACE team ordered to release the trial’s actual data rather than the false, manipulated data they have presented”, and “They’ll appeal but will lose”.

He said, “It’s Alem Matthees who deserves the congratulations for this First-Tier Tribunal decision. He pulled together an incredible brief in arguing his case, and that comes through in the way the decision is written. An amazing piece of work.”

Trevor Butterworth, the director of Sense About Science USA, called the tribunal decision a “major development in transparency” and said that the tribunal had exonerated the ME/CFS community from “harassment” of researchers over the controversial trial. Journalist and ME/CFS patient Julie Rehmeyer tweeted, “Journos who reported PACE researchers got death threats from CFS pts have a moral obligation to report their error.”

Tom Kindlon said, “I hope QMUL won’t make another appeal and waste more taxpayers’ money on a new court case. But whatever they do, they should immediately release the results for the primary outcomes and recovery outcomes as defined in their own protocol that was published before the trial began. Otherwise, people will think that they’ve spent all this time and money on trying to hide inconvenient results. It would have been so much easier for them to have published those requested results when they were asked for them — they could so easily have avoided all this.”

Share on facebook
Share on twitter
Share on whatsapp
Share on google
Share on email

3 thoughts on “QMUL “studying” PACE data-release ruling”

  1. Thank You all so so much!
    I don’t think our gratitude could be any bigger. Regardless of what happens next.
    We’re not used to have a government institution on our side or simply on the side of truth when it comes to ME or CFS. That’s why it all seems so Unreal.
    Many people owe us HUGE apologies although nothing can ever make right what’s been done to us – there are no words for the grief, the humiliation, the neglect, the bodily harm, the Psychological harm.
    Special Thanks Goes to Mr Matthees. Without his courage this would never have happened.

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest News

Choose your top ten ME/CFS research priorities – UK survey launched

Take the survey The ME/CFS Priority Setting Partnership (PSP) is giving you the opportunity to define your top ten priorities for future ME/CFS research. In partnership with the James Lind Alliance, the ME/CFS Priority Setting Partnership is launching their second survey today. The research questions in this survey are based on over 5300 ideas submitted

Read More »

Statement from Forward-ME on NICE Roundtable

After NICE held its roundtable to discuss the new ME/CFS guideline, Forward-ME (which #MEAction UK is a member of) have produced the below statement. Clinician and Patient Support Confirmed for new NICE Guideline on ME/CFS. On Monday, Forward-ME and member charities attended a roundtable to review the new ‘NICE guideline on ME/CFS’ with representatives from

Read More »

Is NIH blowing another opportunity to advance ME/CFS research?

Be sure to attend the telebriefing by the Trans-NIH ME/CFS Working Group this Friday (10/22) at 3PM ET. The National Institutes of Health (NIH) has many questions to answer about its lack of tangible progress or strategic acceleration of medical research for people with ME. Read Our Questions for NIH ME/CFS research opportunity being missed

Read More »

Help keep our work going

We rely on donations from people like you to keep fighting for equality for people with ME.


Get actions alerts and news direct to your inbox

You can choose what you want to be kept up to date on.

Scroll to Top